Publication:
QUINIDINE IN FALCIPARUM MALARIA

dc.contributor.authorNicholas J. Whiteen_US
dc.contributor.authorDavid A. Warrellen_US
dc.contributor.authorDanai Bunnagen_US
dc.contributor.authorSornchai Looareesuwanen_US
dc.contributor.authorTan Chongsuphajaisiddhien_US
dc.contributor.authorTranakchit Harinasutaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNuffield Department of Clinical Medicineen_US
dc.date.accessioned2018-10-12T07:04:45Z
dc.date.available2018-10-12T07:04:45Z
dc.date.issued1981-11-14en_US
dc.description.abstractFourteen patients with falciparum malaria were successfully treated with oral quinidine. Twelve of these patients were followed for 35 days without recrudescence. In six patients the infection had already recrudesced after antimalarial treatment, which in two cases had included a full course of quinine. Quinidine caused no cardiotoxicity, although the electrocardiogram QTcinterval was prolonged by more than 25% in four patients. In-vitro cultures from nine of these patients and a further seven patients with falciparum malaria showed that the minimum inhibitory concentration was consistently lower for quinidine than for quinine. Quinidine is an effective antimalarial drug for Plasmodium falciparum infections and may be more potent than quinine. © 1981.en_US
dc.identifier.citationThe Lancet. Vol.318, No.8255 (1981), 1069-1071en_US
dc.identifier.doi10.1016/S0140-6736(81)91275-7en_US
dc.identifier.issn01406736en_US
dc.identifier.other2-s2.0-0019480346en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/30224
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0019480346&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleQUINIDINE IN FALCIPARUM MALARIAen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0019480346&origin=inwarden_US

Files

Collections